Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating andecaliximab with nivolumab vs nivolumab alone in unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Andecaliximab
• nivolumab (nivolumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-18